NFKB1 and lung adenocarcinoma: To test this hypothesis, an established RNA-seq dataset generated from EGFR-driven human lung adenocarcinoma cells treated acutely with either erlotinib or an NF-κB inhibitor (PBS-1086) or both in combination was examined38.